Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

zoster vaccine recombinant, adjuvanted

A recombinant, subunit herpes zoster (HZ) vaccine containing varicella-zoster virus (VZV) glycoprotein E (gE), that can potentially be used to prevent HZ infection, also called shingles. Upon administration, zoster vaccine recombinant, adjuvanted stimulates the host immune system to induce both specific CD4-positive T-cells and antibodies against VZV gE, thereby protecting against infection with HZ. VZV gE, the most common antigen in VZV viral particles, plays a key role in VZV infection. Compared to live-attenuated vaccines, the subunit vaccine prevents the risk of vaccine-induced HZ in immunocompromised patients.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:herpes zoster subunit vaccine GSK 1437173A
herpes zoster vaccine 1437173A
HZ/su vaccine GSK 1437173A
US brand name:Shingrix
Code name:1437173A
GSK 1437173A
GSK1437173A
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search